Advertisement Fidelity
Home > Boards > US OTC > Medical - Equipment >

MultiCorp International, Inc. (MCIC)

MCIC RSS Feed
Add MCIC Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator sirant, gorbec1, k9narc, MLR_Lite, 4u2nv2, stringofpearls
Search This Board:
Last Post: 4/20/2014 3:01:39 PM - Followers: 519 - Board type: Free - Posts Today: 12
http://multicorpinternational.com


 

Medical

The medical industry has seen many changes in the past few years, and MultiCorp will continue to operate in this sector. When identifying potential acquisitions in this sector, MultiCorp has a significant advantage over other companies looking for qualified businesses.

Our past work with major healthcare companies such as United Healthcare, Kaiser, and Tenet, to name a few, bodes well for MultiCorp's future. As with any new technology in the medical field, working with the actual companies that can pay for the products/services is the key to generating revenue in this sector.

MultiCorp will look to grow its business now and in the future by identifying breakthroughs in the tele-medicine and tele-health sectors, hospital and clinic construction and operations, healthcare insurance and managed professional groups.

The company has submitted bids throughout the world to build and operate several hospitals, clinics, and other similar medical businesses that offer cutting-edge solutions for countries that have been lagging behind in delivering proper medical care.

The company is also looking to penetrate all facets of the Obamacare solutions for patients and companies that are having a hard time navigating this system. Through alliances with healthcare insurers, medical professionals, and software solution companies, MultiCorp expects to grow in the medical sector for many years to come.
 

MULTICORP INTERNATIONAL, INC ENGAGES BIOREGENERATIVE SCIENCES, INC and NORTH COUNTY CLINICAL RESEARCH TO DEVELOP CLINICAL TRIAL PROCEDURES ON PATENTED MIGRAINE MEDICINE

Apr 16, 2014

OTC Disclosure & News Service
Sun Valley, CA -
Procedure Report will Set Stage to begin Clinical Trials on Migraine Medication
April 16, 2014 6:00 AM PT
SUN VALLEY, CA - MultiCorp International, Inc, (OTC Pink: MCIC - News) has engaged Dr. Greg Maguire of BioRegenerative Sciences, Inc along with Dr. Valentin Isacescu of North County Clinical Research to work with the company to develop a clear path to begin clinical trials on their patented migraine medicine for eventual approval by the FDA.
The company released the following statement, "We're extremely excited to have such a qualified and experienced group to assist the company in mapping out a clear strategy for the migraine medication to gain approval from the FDA. While we understand this could be a long process, having a group that is so well versed on the proper procedures clinical trials require to gain approval, we feel we've chosen the perfect group to accomplish this portion of the process in the most expeditious manner possible. Once the report is completed in the next four to six weeks, the company will have a clear understanding as to the requirements from the FDA on beginning clinical trials", stated Mr. Paul D. Lisenby, CEO of MultiCorp International, Inc. Mr. Lisenby added, "We feel this medication could become a major player in the $3.2 billion dollar segment of the migraine pharmaceutical vertical."
Dr. Greg Maguire, CEO of BioRegenerative Sciences, Inc, stated, "Our group is very excited to help bring this important new drug candidate for migraines through the FDA 505(b)(2) NDA approval process. Dr Valentin Isacescu added, "Migraine is such a debilitating disorder for so many patients and a tremendous need exists for a medication to prevent and control this malady."  
About MultiCorp International, Inc.
MultiCorp International, Inc is a diverse company that operates in various business sectors that show true growth potential. The company builds on its executives experience in property development, constructions, medical, hospitality, agribusiness, commodities such as oil and gas, and entertainment. The company looks to expand through acquisitions of solid business models and management that have the potential to grow exponentially. The company will have additional subsidiaries that will eventually grow into being their own public entity, be sold, or continue to operate within MultiCorp. For further information please contact them at info@multicorpinternational.com
 
About BioRegenerative Sciences, Inc.
BioRegenerative Sciences, Inc. is a privately held corporation headquartered in San Diego, CA and currently has fifteen patent pending products on the market and is further developing a portfolio of therapeutic and cosmeceutical products and services based on BRS's core stem cell-based S2RM(R) Technology.  For more information, please email: sales@bioregenerativesciences.com, or call BRS at 858. 521.9203.
 
About North County Clinical Research
North County Clinical Research (NCCR) is a dedicated clinical research site located in the North County of San Diego. We specialize in central nervous system (CNS) indications, some medical indications, drug dependence, alcohol dependence, nicotine dependence, sleep disorders, and chronic pain clinical trials. We are comprised of physicians and research staff with over 20 years of combined experience conducting phase II through phase IV clinical trials. Our site is affiliated with Aurora Behavioral Health Care which provides excellent opportunities for recruitment and inpatient clinical trials.
For more information, please visit their website at http://www.nccresearch.com/







Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication

 

Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication

Company Seeking Clinical Trial Partner to Begin Testing in First Quarter of 2014

SUN VALLEY, CA--(Marketwired - Dec 17, 2013) - MultiCorp International, Inc, (OTC Pink: MCIC) has acquired a 70% stake in a patented migraine medication. The company released the following statement:

"MultiCorp International, Inc has acquired a 70% ownership in a patented migraine medicine that has shown to aid in the symptoms of migraine headaches. According to www.migraine.com in the U.S. alone more than 37 million people suffer from migraines and globally over 330 million people have migraines on a constant basis. The medication was developed by a physician that MultiCorp will work closely with in order to gain FDA approval for the medication. The company plans to begin clinical trials in the first quarter of 2014 and hope to have the medication to market as soon as possible. The information on the patent can be found at http://www.faqs.org/patents/app/20090018205. Under the terms of the agreement, MultiCorp will have full authority to oversee the clinical trials of the product, marketing and selling of the medication, as well the overall business of getting the product to market as quickly as possible and retaining a 70% interest in the product. With the average cost of $145 per month in medication for migraine sufferers, the market for this product is exponential here in the U.S. and globally."

For companies wishing to assist MultiCorp in clinical trials, please email us at info@multicorpinternational.com

 

 

About MultiCorp International

MultiCorp International, Inc is a diverse company that operates in various business sectors that show true growth potential. The company builds on its executives experience in property development, constructions, medical, and hospitality as well as commodities such as oil and gas, and entertainment.

MultiCorp seeks out and acquires companies in several targeted business fields that have strong potential, seasoned management experience, and show true potential for exponential growth.

While our process may seem simple to some - look for and acquire companies in growth sectors - our standards are set high. A complete due diligence package must be met before any consideration is made to move forward. If, at any time, any component of our criteria is not met, that potential business will not be considered to become part of MultiCorp International, Inc.

MultiCorp will continue to build and grow in the future. Our expansion will be global in nature and the company continues to look at projects/companies throughout the world. The vision of management for MultiCorp is to diversify into many fields wherein management's expertise along with our strategic partners experience will raise the company's bottom line profitability
 

Management

Paul D. Lisenby - Chairman and CEO
Mr. Lisenby has been in the capital markets since 1996. Paul managed a $100 million fund that invested in small cap companies, large indexes as well as private equity funding. In addition, Paul was responsible for negotiating several acquisitions to include a software company valued at $186 million dollars as well as several other companies that brought in over $200 million in revenue throughout his executive career. Mr. Lisenby has been at the helm of MultiCorp since its inception in 2007 as XTend Medical. Mr. Lisenby holds a BA and MBA.

Ben Friedman - President
Mr. Friedman has worked in the medical and pharmacology business for over 35 years. A licensed pharmacist, Mr. Friedman has overseen developing several proprietary prescription compounds and several OTC medications throughout his career. In addition, Ben owned hotels and other properties he's developed. Ben also has been working in the capital markets since 2005 wherein his financial acumen has helped companies raise in excess of $15 million in private funding. Mr. Friedman currently holds a BA in business and is currently licensed to practice pharmacy in California and hold his board certification in pharmacology


 






 



 


 



 

AS info DE. Dept. of Corp. 

24/7 Phone: 302-739-3073, press #8 file number 3866564
http://www.corp.delaware.gov/default.shtml
Note: Web site does not give the AS. Must call, automated 24/7, or during business hours if one wishes to speak in person. 

Company Information

 MultiCorp International, Inc
10771 Sherman Way
Sun Valley, CA 91352
Phone: (818) 255-2476
Fax: (818) 255-2122

 Transfer Agent

Signature Stock Transfer, Inc.

2632 Coachlight Ct.
Plano, TX75093
Phone972-612-4120 Fax972-612-4122

Email - signaturestocktransfer@msn.com

      

 

This board is for discussing XMDC.
Information posted either positive or negative is accepted.
Personal attacks, repetitive, off topic posts or outright flame baiting posts are not accepted.
Posts that respond to PM (One way messages) are not allowed. Vulgarity is not acceptable. Violation of ones privacy is not acceptable.

Posts in violation of the rules will be deleted. Repeat offenders will be reported to the admins of IHUB.


Rules of the board per IHUB:
http://www.investorshub.com/boards/complex_terms.asp
 

 
Share structure

As of 06/18/08: 28,437,031 shares outstanding: 21,403,469 shares free trading: 7,033,562 shares restricted
As of 07/01/08: 28,437,031 shares outstanding: 21,403,469 shares free trading: 7,033,562 shares restricted
As of 07/03/08: 28,437,031 shares outstanding: 21,403,469 shares free trading: 7,033,562 shares restricted
As of 07/14/08: 28,437,031 shares outstanding: 21,403,469 shares free trading: 7,033,562 shares restricted
As of 07/16/08: 31,237,031 shares outstanding: 24,203,809 shares free trading: 7,033,562 shares restricted
As of 07/23/08: 36,737,031 shares outstanding: 30,057,796 shares free trading: 6,679,235 shares restricted; 150,000,000 shares Authorized.
As of 08/06/08: 36,737,031 shares outstanding: 30,057,796 shares free trading: 6,679,235 shares restricted; 150,000,000 shares Authorized.
As of 08/13/08: 36,737,031 shares outstanding: 30,057,796 shares free trading: 6,679,235 shares restricted; 150,000,000 shares Authorized.
As of 08/22/08: 86,737,031 shares outstanding: 80,057,796 shares free trading: 6,679,235 shares restricted; 1,000,000,000 shares Authorized.
As of 08/25/08: 101,737,031 shares outstanding: 95,057,796 shares free trading: 6,679,235 shares restricted; 1,000,000,000 shares Authorized.
As of 09/02/08: 245,737,031 shares outstanding: 239,489,809 shares free trading: 6,247,222 shares restricted; 1,000,000,000 shares Authorized.
As of 07/21/09: 256,737,031 shares outstanding: 239,065,599 shares free trading: 17,671,432 shares restricted; 1,000,000,000 shares Authorized.
As of 09/22/09: 256,737,031 shares outstanding: 239,065,599 shares free trading: 17,671,432 shares restricted; 1,000,000,000 shares Authorized.
As of 10/05/09: 616,737,031 shares outstanding: 299,065,600 shares free trading: 317,671,431 shares restricted; 1,000,000,000 shares Authorized.
As of 10/05/09: 616,737,031 shares outstanding: 299,065,600 shares free trading: 317,671,431 shares restricted; 1,000,000,000 shares Authorized.
As of 10/27/09: 636,737,031 shares outstanding: 319,497,611 shares free trading: 317,671,431 shares restricted; 1,000,000,000 shares Authorized.
As of 11/04/09: 649,737,031 shares outstanding: 332,065,600 shares free trading: 317,671,431 shares restricted; 1,000,000,000 shares Authorized.
As of 11/09/09: 766,487,031 shares outstanding: 351,681,600 shares free trading: 414,805,431 shares restricted; 1,000,000,000 shares Authorized.
As of 11/18/09: 770,487,031 shares outstanding: 355,681,600 shares free trading: 414,805,431 shares restricted; 1,000,000,000 shares Authorized.
As of 12/03/09: 783,137,031 shares outstanding: 370,891,600 shares free trading: 412,245,431 shares restricted; 1,000,000,000 shares Authorized.
As of 12/10/09: 986,490,863 shares outstanding: 378,391,600 shares free trading: 608,099,263 shares restricted; 1,000,000,000 shares Authorized.
As of 02/01/10: 986,490,863 shares outstanding: 390,766,744 shares free trading: 595,724,119 shares restricted; 1,000,000,000 shares Authorized.
As of 02/12/10: 986,490,863 shares outstanding: 390,766,744 shares free trading: 595,724,119 shares restricted; 1,000,000,000 shares Authorized.
As of 10/17/10: 986,490,863  shares outstanding: 390,766,744 shares free trading: 595,724,119 shares restricted; 1,750,000,000 shares Authorized.
As of 12/31/11  1,384,887,031 shares outstanding:462,855,646 shares free trading: 922,031,385 shares restricted:1,750,000,000 shares Authorized.
As of 08/30/12  984,887,031 shares outstanding: : 462,885,646 Free Trading : 1,750,000,000 shares Authorized.


SHAREHOLDERS' EQUITY, Per Company Balanced sheet
As of Sept 30, 2012 the company has 1,392,887,031
shares of common stock issued and outstanding.


 

 

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MCIC
Current Price
Volume:
Bid Ask Day's Range
Wiki
MCIC News: MultiCorp International, Inc. Engages BioRegenerative Sciences, Inc. & North County Clinical Research to Develop Clinical Tri... 04/17/2014 01:40:00 PM
MCIC News: Multicorp International, Inc Acquires 70% Ownership in Patented Migraine Headache Medication 12/17/2013 09:00:00 AM
PostSubject
#180102  Sticky Note Yea. NCCR looks to me to be more 4u2nv2 04/16/14 08:39:28 PM
#180075  Sticky Note MULTICORP INTERNATIONAL, INC ENGAGES BIOREGENERATIVE SCIENCES, INC and 4u2nv2 04/16/14 10:32:02 AM
#180294   I believe better than that? JMHO sirant 04/20/14 03:01:39 PM
#180293   I agree it is ready to run.... jonblair77 04/20/14 02:07:14 PM
#180292   Time For Another Nice Run, Back To A Mark280z 04/20/14 02:04:56 PM
#180291   Thanks you too have a great Easter. sirant 04/20/14 11:35:06 AM
#180290   happy easter everyone enjoy the day gorbec1 04/20/14 11:18:20 AM
#180289   What doctor are you referring to? Also, what DKLN 04/20/14 08:27:29 AM
#180288   Time will tell, But we know that this jonblair77 04/20/14 08:26:54 AM
#180287   How about the pps reach .01 (with decent DKLN 04/20/14 08:15:24 AM
#180286   Yes I agree but think that's minimum? sirant 04/20/14 07:26:11 AM
#180285   LAST 2 YEARS HAE BEEN A DEBACLE. patriot4life 04/20/14 07:21:58 AM
#180284   15 cents to 25 cents for sure. patriot4life 04/20/14 07:18:42 AM
#180283   Yes made Money here before and believe i sirant 04/20/14 02:52:59 AM
#180282   That's what zero accomplishments and BS (e.g., timelines DKLN 04/19/14 09:47:28 PM
#180281   MCIC one wasn't even in the running for k9narc 04/19/14 09:36:17 PM
#180280   I agree that Lisenby has ripped off investors DKLN 04/19/14 09:30:46 PM
#180279   Why try to support a CEO who has DKLN 04/19/14 09:22:56 PM
#180278   We are due for run the question is jonblair77 04/19/14 06:59:04 PM
#180277   I believe this is the start of a sirant 04/19/14 06:38:01 PM
#180276   Down 20 on 1-2 million. k9narc 04/19/14 06:35:44 PM
#180275   $MCIC rocks up 20% on only 5 million sirant 04/19/14 05:46:35 PM
#180274   Why Dwell On The Past, PPS Has Been Mark280z 04/19/14 05:41:05 PM
#180273   Yes Paul should be ceo of the year sirant 04/19/14 05:40:41 PM
#180272   Uh-no. This stock is a pathetic .0042 and DKLN 04/19/14 05:38:06 PM
#180271   I believe this is the start of a sirant 04/19/14 03:34:54 PM
#180270   What happened to the saint who said something DKLN 04/19/14 02:47:09 PM
#180269   Looks like the volume is putrid. Looks like DKLN 04/19/14 02:43:54 PM
#180267   I believe that 95% of the shareholders believe sirant 04/19/14 02:10:14 PM
#180265   looks like we been going gorbec1 04/19/14 12:56:56 PM
#180264   Have you seen Lisenby spew his alleged plans DKLN 04/19/14 12:17:11 PM
#180263   Not pumping, I have agreed with you in jonblair77 04/19/14 12:08:43 PM
#180260   It doesn't matter whose plan it is. Potential DKLN 04/19/14 11:39:22 AM
#180259  Restored It won't be his plan since he is jonblair77 04/19/14 11:16:03 AM
#180258   Potential investors are not interested in Lisenby's plans. DKLN 04/19/14 11:00:40 AM
#180257   Looks like great partners.... jonblair77 04/19/14 10:35:28 AM
#180256   glad they are working with us gorbec1 04/19/14 10:30:51 AM
#180255   MultiCorp International, Inc. Engages BioRegenerative Sciences, Inc. and gorbec1 04/19/14 10:10:25 AM
#180254   I am looking forward to "Hopefully" regular news..... jonblair77 04/19/14 08:44:31 AM
#180253   A stock that is under .01 and has DKLN 04/19/14 08:37:50 AM
#180252   I just hope he starts to put our jonblair77 04/19/14 08:26:31 AM
#180251   I believe people will read it over the sirant 04/19/14 08:03:15 AM
#180250   Wish the news hit the major wire on jonblair77 04/19/14 07:44:56 AM
#180249   $MCIC Looking good Monday should be interesting. JMHO sirant 04/19/14 07:34:16 AM
#180248   For the previous two years it was buy DKLN 04/19/14 06:52:54 AM
#180247   For those who have done some DD on MLR_Lite 04/19/14 03:11:18 AM
#180246   Buy Sub-Penny . . Sell At A Dime Mark280z 04/18/14 11:09:19 PM
#180245  Restored During the previous two years, it was buy DKLN 04/18/14 10:17:54 PM
#180244   We have always had a lot of people jonblair77 04/18/14 10:17:53 PM
#180243   Nice Volume And PPS Headed Back To A Mark280z 04/18/14 09:50:34 PM
#180242   My gues this has been being looked at gorbec1 04/18/14 09:07:00 PM
#180241   But why do most potential investors not care DKLN 04/18/14 08:46:39 PM
PostSubject